Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 4.64B +205.1% |
| Revenue (ttm) | n/a |
| Net Income | -197.22M |
| EPS | -1.85 |
| Shares Out | 108.60M |
| PE Ratio | n/a |
| Forward PE | 29.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 739,627 |
| Open | 43.84 |
| Previous Close | 44.19 |
| Day's Range | 42.72 - 44.19 |
| 52-Week Range | 13.69 - 48.40 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 51.69 (+20.88%) |
| Earnings Date | Aug 6, 2026 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $51.69, which is an increase of 20.88% from the latest price.
News
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026...
Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan
JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $60 from $53 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Edgewise Therapeutics (EWTX) to $36 from $32 and keeps a Neutral rating on the shares.
Edgewise Therapeutics reports Q2 EPS (53c), consensus (47c)
Cash, cash equivalents and marketable securities were approximately $460.7M as of June 30, 2026. “In Q2, Edgewise entered into a deal to sell sevasemten and our muscular dystrophy business to…
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and muscul...
Edgewise Therapeutics Quarterly report: Q2 2026
Edgewise Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Edgewise Therapeutics Earnings release: Q2 2026
Edgewise Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
Evercore ISI analyst Cory Kasimov raised the firm’s price target on Edgewise Therapeutics (EWTX) to $55 from $45 and keeps an Outperform rating on the shares after updating the firm’s…
Edgewise Therapeutics completes sale of sevasemten for up to $2.65B
Edgewise Therapeutics (EWTX) announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a f...
Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4
Based on recent positive 12-week data from Part D of the CIRRUS-HCM Phase 2 trial of EDG-7500, which included safety, echocardiographic, biomarker, and patient-reported outcome assessments across both...
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular co...
Edgewise Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Edgewise Therapeutics (EWTX) with an Outperform rating and $51 price target The firm notes the company that just delivered on a derisking Phase 2 readout, monetized…
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Edgewise Therapeutics (EWTX) to $51 from $41 and keeps a Buy rating on the shares. The firm updated its model…
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...
Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital
RBC Capital raised the firm’s price target on Edgewise Therapeutics (EWTX) to $59 from $48 and keeps an Outperform rating on the shares. The company reported 12 week results from…
Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Edgewise Therapeutics (EWTX) to $32 from $20 and keeps a Neutral rating on the shares. Phase 2 CIRRUS-HCM data…
Edgewise Therapeutics price target raised to $52 from $50 at Leerink
Leerink raised the firm’s price target on Edgewise Therapeutics (EWTX) to $52 from $50 and keeps an Outperform rating on the shares. The firm continues to think that CIRRUS Part…
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
Edgewise Therapeutics falls -9.9%
Edgewise Therapeutics (EWTX) is down -9.9%, or -$3.50 to $31.71.
Edgewise Therapeutics Transcript: Study result
EDG-7500 demonstrated robust safety and efficacy in both obstructive and non-obstructive HCM, with significant improvements in gradients, biomarkers, and patient-reported outcomes, and no evidence of systolic liability. The results support echo-independent dosing and set the stage for phase III trials.
Edgewise Therapeutics Press release: Study result
Edgewise Therapeutics issued a press release on June 16, 2026, disclosing material business information to investors.
Edgewise Therapeutics Slides: Study result
Edgewise Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Edgewise Therapeutics down 25% at $26.55 after EDG-7500 trial update
07:50 EDT Edgewise Therapeutics (EWTX) down 25% at $26.55 after EDG-7500 trial update
Edgewise Therapeutics’ EDG-7500 shows improvements in cardiomyopathy
Edgewise Therapeutics (EWTX) announced positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in obstructive, or oHCM, and nonobstructive, or nHCM, nonobstructive hyper...
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, sym...